Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 181,540 shares of CRSP, which is worth approximately $7.39 Million. The most recent transaction as insider was on Mar 29, 2023, when has been sold 25,000 shares (Common Shares) at a price of $44.57 per share, resulting in proceeds of $1,114,250. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 182K

18.41% 3M change

53.14% 12M change

Total Value Held $7.39 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 29 2023	SELL Open market or private sale	$1,114,250 $44.57 p/Share	25,000 Reduced 6.06%	387,377 Common Shares
Mar 29 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.72%	412,377 Common Shares
Mar 13 2023	SELL Payment of exercise price or tax liability	$408,169 $43.22 p/Share	9,444 Reduced 2.38%	387,377 Common Shares
Mar 11 2023	BUY Exercise of conversion of derivative security	-	9,000 Added 2.25%	391,463 Common Shares
Mar 10 2023	BUY Exercise of conversion of derivative security	-	11,833 Added 2.96%	387,821 Common Shares
Feb 27 2023	SELL Open market or private sale	$1,212,250 $48.49 p/Share	25,000 Reduced 6.23%	375,988 Common Shares
Feb 27 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.87%	400,988 Common Shares
Feb 21 2023	SELL Payment of exercise price or tax liability	$307,560 $48.26 p/Share	6,373 Reduced 1.67%	375,988 Common Shares
Feb 18 2023	BUY Exercise of conversion of derivative security	-	13,250 Added 3.35%	382,361 Common Shares
Jan 27 2023	SELL Open market or private sale	$1,276,750 $51.07 p/Share	25,000 Reduced 6.34%	369,111 Common Shares
Jan 27 2023	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.97%	394,111 Common Shares
Dec 28 2022	SELL Open market or private sale	$1,028,250 $41.13 p/Share	25,000 Reduced 6.34%	369,111 Common Shares
Dec 28 2022	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 5.97%	394,111 Common Shares
Dec 06 2022	BUY Exercise of conversion of derivative security	$105,401 $1.81 p/Share	58,233 Added 13.63%	369,111 Common Shares
Dec 05 2022	SELL Payment of exercise price or tax liability	$1,013,896 $52.26 p/Share	19,401 Reduced 5.87%	310,878 Common Shares
Dec 03 2022	BUY Exercise of conversion of derivative security	-	40,000 Added 10.8%	330,279 Common Shares
Nov 28 2022	SELL Open market or private sale	$1,365,250 $54.61 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Nov 28 2022	BUY Exercise of conversion of derivative security	$478,000 $19.12 p/Share	25,000 Added 7.35%	315,279 Common Shares
Oct 26 2022	SELL Open market or private sale	$1,359,000 $54.36 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Oct 26 2022	BUY Exercise of conversion of derivative security	$441,750 $17.67 p/Share	25,000 Added 7.35%	315,279 Common Shares
Sep 28 2022	SELL Open market or private sale	$1,619,500 $64.78 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Sep 28 2022	BUY Exercise of conversion of derivative security	$405,250 $16.21 p/Share	25,000 Added 7.35%	315,279 Common Shares
Aug 29 2022	SELL Open market or private sale	$1,673,000 $66.92 p/Share	25,000 Reduced 7.93%	290,279 Common Shares
Aug 29 2022	BUY Exercise of conversion of derivative security	$405,250 $16.21 p/Share	25,000 Added 7.35%	315,279 Common Shares
Jul 27 2022	SELL Open market or private sale	$1,915,750 $76.63 p/Share	25,000 Reduced 7.93%	290,279 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director